News Related to Nordic AML Group

Related coverage linked through entity extraction aliases.

Faron's Bexmarilimab Data Accepted for BSH Presentation; New AML Study Launched

Feb 24, 2026

Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.

Faron Initiates Phase II BEAM-X Trial for Post-Transplant AML Relapse Prevention

Feb 19, 2026

Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.